Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Clinical trial NCT06475235 · RECRUITING

Trial details

NCT number: NCT06475235
Sponsor: Dana-Farber Cancer Institute
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoma Primary Central Nervous System Lymphoma

Start date: 2024-10-18
Primary completion: 2026-12-30
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.